FDA Approves Olaparib for Frontline Maintenance in Pancreatic Cancer

December 30, 2019 – The FDA has approved the PARP inhibitor olaparib for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. The approval is based on data from the phase III POLO trial, which showed a progression-free survival (PFS) benefit with olaparib compared with placebo in this setting … (leggi tutto)